Evidence map›Paper›PMID 40839290›Full record

ArticleSports medicine - open2025

The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial.

Ayshe Sahinovic, Namson S Lau, Angelo Sabag, Rebecca Gordon, Amanda J Cox, Katie Walker, Christopher Irwin, Ben Desbrow, Nathan Johnson, Paul J Austin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sports medicine - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ayshe SahinovicLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia. ayshe.sahinovic@sydney.edu.au.ORCID http://orcid.org/0000-0003-0717-2342
Namson S LauThe Boden Initiative, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Angelo SabagCharles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Rebecca GordonLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Amanda J CoxSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
Katie WalkerLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Christopher IrwinSchool of Allied Health, Sport and Social Work, Griffith University, Gold Coast, QLD, Australia.
Ben DesbrowSchool of Allied Health, Sport and Social Work, Griffith University, Gold Coast, QLD, Australia.
Nathan JohnsonCharles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Paul J AustinSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Paul HaberCentral Clinical School, The University of Sydney, Sydney, NSW, Australia.
Iain S McGregorLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Danielle McCartneyLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia. danielle.mccartney@sydney.edu.au.ORCID http://orcid.org/0000-0002-7783-5220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAthletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclear. This study investigated the acute effects of a low, nutraceutical (50 mg) and moderate, therapeutic (300 mg) dose of CBD on physiological and subjective responses to endurance exercise in trained runners.

resultsA randomised double-blind, placebo-controlled, crossover clinical trial was conducted at the University of Sydney between 24th October 2022 and 4th March 2024. Twenty-five participants (16 male;

conclusionsCBD (50 mg, 300 mg; acute) does not appear to alter the subjective experience of submaximal intensity exercise, impact endurance performance (i.e., TTE) or have compelling effects on physiological responses to exercise. Use of CBD by athletes is, therefore, unlikely to be ergolytic or ergogenic at low to moderate doses.

trial registrationThe trial was approved by the Sydney Local Health District's Human Research Ethics Committee (2021/ ETH11945; X21-0392) and registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752).

Identifiers

PMID40839290
PMCPMC12370602

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.